RecruitingPhase 1NCT07195175

Study of MAR002 in Healthy Men

First in Human, Randomized, Blinded, Placebo-Controlled Single Ascending Dose and Multiple Dose Study of MAR002 in Healthy Men

Sponsor

Marea Therapeutics

Enrollment

45 participants

Start Date

Aug 11, 2025

Study Type

INTERVENTIONAL

Conditions

Acromegaly

Summary

Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men

Eligibility

Sex: MALEMin Age: 18 YearsMax Age: 40 Years

Inclusion Criteria5

Willingness to provide written informed consent
Age 18 to 40
Weight 55 to 95 kg
Body mass index (BMI) 18 to 30 kg/m2
Healthy men

Exclusion Criteria9

History of hypersensitivity to monoclonal antibodies or study drug
Participation in any other investigational drug study
History of cancer
Recent acute illness
Positive test for HIV, hepatitis B/C
History of substance abuse or nicotine use
Recent blood donation
History of pituitary disorder
Any condition that prevents the participant from complying with study procedures

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMAR002

subcutaneous injection

DRUGPlacebo

Subcutaneous injection

Locations(1)

Marea Site

Tempe, Arizona, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07195175

Related Trials

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT0693062571 locations

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

NCT0703742045 locations